Hidradenitis Suppurativa (HS) Clinical Trial
Official title:
A Phase 3 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa - PIONEER I
A study to evaluate the safety and efficacy of treatment with adalimumab in adults with moderate to severe hidradenitis suppurativa (HS).
The clinical trial identifier is PIONEER I. The purpose of this study is to evaluate the safety of adalimumab and to determine how well it works in the treatment of adults with moderate to severe HS. HS is a chronic skin disease that creates red, swollen, painful bumps which can break open to combine and form tunnels in the skin and scars. Sometimes these bumps can heal themselves quickly and sometimes they will become much worse and create sores that heal with multiple combined scars, or areas that do not heal. In this study, approximately 300 adults will be enrolled at treatment centers worldwide. Subject participation in this study will be up to 50 weeks. There will be a screening period, which will last from 7 to 30 days, and a study treatment period of up to 36 weeks. Study visits occur at Screening, Baseline, and Weeks 2, 4, 8, 12, 14, 16, 20, 24, 28, 32 and 36 (or sooner if subject leaves the study before Week 36). The study is divided into two treatment periods. The first period (Period A) will last 12 weeks and the second period (Period B) will last up to 24 weeks. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03173144 -
Chronic Inflammatory Disease, Lifestyle and Treatment Response
|
||
| Completed |
NCT02896920 -
Canadian Humira Post Marketing Observational Epidemiological Study : Assessing Humira Real-life Effectiveness and Impact on HS Burden of Illness
|
||
| Completed |
NCT01468233 -
Efficacy and Safety Study of Adalimumab in the Treatment of Hidradenitis Suppurativa
|
Phase 3 | |
| Completed |
NCT03894956 -
Observational Study Evaluating Long-Term Safety and Effectiveness of Humira in Patients With Hidradenitis Suppurativa
|
||
| Completed |
NCT03001115 -
Post-Marketing Surveillance of Adalimumab in Korean Hidradenitis Suppurativa Subjects
|
||
| Not yet recruiting |
NCT05723757 -
Autophagy Dysfunction in Hidradenitis Suppurativa
|
N/A | |
| Completed |
NCT02808975 -
Safety and Efficacy of Adalimumab (Humira) for Hidradenitis Suppurativa (HS) Peri-Surgically
|
Phase 4 | |
| Completed |
NCT04430855 -
A Study of Oral Upadacitinib Tablet Compared to Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa to Assess Change in Disease Symptoms
|
Phase 2 | |
| Recruiting |
NCT06212999 -
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa
|
Phase 3 | |
| Active, not recruiting |
NCT04354012 -
Hidradenitis Suppurativa Wound Care
|
Phase 2 | |
| Completed |
NCT03487276 -
Efficacy and Safety Study of IFX-1 in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)
|
Phase 2 | |
| Recruiting |
NCT05620836 -
A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa (HS)
|
Phase 3 | |
| Not yet recruiting |
NCT05735925 -
The Role of Host-microbiota Interplay in Hidradenitis Suppurativa Pathogenesis
|
N/A | |
| Recruiting |
NCT05620823 -
A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa
|
Phase 3 | |
| Recruiting |
NCT06241573 -
A Study to Test Long-term Treatment With Spesolimab in People With a Skin Condition Disease Called Hidradenitis Suppurativa (HS) Who Took Part in a Previous Study With Spesolimab
|
Phase 2/Phase 3 | |
| Available |
NCT05583604 -
Secukinumab Global MAP Cohort for Adult Patients With Hidradenitis Suppurativa (HS)
|